NCT06020144View on ClinicalTrials.gov

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

PHASE3RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

September 30, 2025

Conditions
Rheumatoid Arthritis
Interventions
DRUG

TLL-018

Oral tablets administered 2pieces BID for 52 weeks.

DRUG

Tofacitinib

Oral tablets administered 1pieces BID for 52 weeks.

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Hangzhou Highlightll Pharmaceutical Co., Ltd

INDUSTRY